Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Conclusions: We report the case of a patient with SDC treated with T-DM1, with a very good response. Salivary carcinoma is a rare disease for which no randomized clinical trials are available. The maintenance of HER2 blockage might be important in this disease.Case Rep Oncol 2018;11:252 –257
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Hepatocellular Carcinoma | HER2 | Herceptin | Liver | Liver Cancer | Parotidectomy | PET Scan | Rare Diseases | Skin | Toxicology | Urology & Nephrology